Stock Track | Moderna Soars 5.16% Intraday as Analyst Price Target Hikes Boost Investor Confidence

Stock Track

Aug 03

Shares of Moderna, Inc. (MRNA) surged 5.16% during intraday trading on Monday, as a wave of bullish analyst actions lifted the biotechnology stock. The rally came after UBS raised its price target on the company to $50 from $45 while maintaining a neutral rating, and BofA Global Research also increased its price objective to $40 from $38.

The positive sentiment was further reinforced by Moderna's recent second-quarter earnings report, which beat revenue estimates and showed a smaller-than-expected loss per share, driven by lower research and development spending. The company is also approaching a key U.S. regulatory decision for its flu vaccine, which has kept investor attention focused on the stock.

Analyst coverage overall has been mixed, with a consensus hold rating and a mean price target of $53.79 according to FactSet, but the back-to-back price target increases from major firms signaled growing confidence in Moderna's near-term outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1126356284"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126356284\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126356284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126356284","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.16% Intraday as Analyst Price Target Hikes Boost Investor Confidence","media":"Stock Track","content":"<p>Shares of Moderna, Inc. (MRNA) surged 5.16% during intraday trading on Monday, as a wave of bullish analyst actions lifted the biotechnology stock. The rally came after UBS raised its price target on the company to $50 from $45 while maintaining a neutral rating, and BofA Global Research also increased its price objective to $40 from $38.</p><p>The positive sentiment was further reinforced by Moderna's recent second-quarter earnings report, which beat revenue estimates and showed a smaller-than-expected loss per share, driven by lower research and development spending. The company is also approaching a key U.S. regulatory decision for its flu vaccine, which has kept investor attention focused on the stock.</p><p>Analyst coverage overall has been mixed, with a consensus hold rating and a mean price target of $53.79 according to FactSet, but the back-to-back price target increases from major firms signaled growing confidence in Moderna's near-term outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.16% Intraday as Analyst Price Target Hikes Boost Investor Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.16% Intraday as Analyst Price Target Hikes Boost Investor Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-03 22:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Moderna, Inc. (MRNA) surged 5.16% during intraday trading on Monday, as a wave of bullish analyst actions lifted the biotechnology stock. The rally came after UBS raised its price target on the company to $50 from $45 while maintaining a neutral rating, and BofA Global Research also increased its price objective to $40 from $38.</p><p>The positive sentiment was further reinforced by Moderna's recent second-quarter earnings report, which beat revenue estimates and showed a smaller-than-expected loss per share, driven by lower research and development spending. The company is also approaching a key U.S. regulatory decision for its flu vaccine, which has kept investor attention focused on the stock.</p><p>Analyst coverage overall has been mixed, with a consensus hold rating and a mean price target of $53.79 according to FactSet, but the back-to-back price target increases from major firms signaled growing confidence in Moderna's near-term outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1126356284","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126356284","pubTimestamp":1785766714,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Moderna, Inc. (MRNA) surged 5.16% during intraday trading on Monday, as a wave of bullish analyst actions lifted the biotechnology stock. The rally came after UBS raised its price target on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | Moderna 盘中飙升 5.16%，分析师上调目标价提振投资者信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Shares of Moderna, Inc. (MRNA) surged 5.16% during intraday trading on Monday, as a wave of bullish analyst actions lifted the biotechnology stock. The rally came after UBS raised its price target on the company to $50 from $45 while maintaining a neutral rating, and BofA Global Research also increased its price objective to $40 from $38.The positive sentiment was further reinforced by Moderna's recent second-quarter earnings report, which beat revenue estimates and showed a smaller-than-expected loss per share, driven by lower research and development spending. The company is also approaching a key U.S. regulatory decision for its flu vaccine, which has kept investor attention focused on the stock.Analyst coverage overall has been mixed, with a consensus hold rating and a mean price target of $53.79 according to FactSet, but the back-to-back price target increases from major firms signaled growing confidence in Moderna's near-term outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}